Ebola Virus Infection
5
0
0
2
Key Insights
Highlights
Success Rate
50% trial completion
Treatment Research
6 treatments under study, led by Acurrent Standard Of Care Alone
Research Leaders
14 sponsors active, led by Arbutus Biopharma Corporation
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 77/100
40.0%
2 terminated out of 5 trials
50.0%
-36.6% vs benchmark
20%
1 trials in Phase 3/4
50%
1 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 2 completed trials
Clinical Trials (5)
Immunity Induced by VSV-EBOV and Assessment of a Booster Dose in Individuals at Potential Occupational Risk for Exposure
Putative Investigational Therapeutics in the Treatment of Patients With Known Ebola Infection
A Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BCX4430
Safety, Tolerability and Pharmacokinetic First in Human (FIH) Study for Intravenous (IV) TKM-100802
Safety, Tolerability and Pharmacokinetic First in Human (FIH) Study of Intravenous (IV) TKM-100201 Infusion
Research Network
Common Treatments
- Acurrent Standard Of Care Alone1
- Tkm1002011
- Ervebo Rvsvgzebovgp1
- Tkm100802 For Injection1
- Bcx44301
Active Sponsors
- Arbutus Biopharma Corporation2
- United States Department of Defense2
- National Institute of Allergy and Infectious Diseases (NIAID)2
- The Ministry of Health and Social Welfare, Liberia1
- University Medical Center Hamburg-Eppendorf1
Top Investigators
Universitätsklinikum Hamburg-Eppendorf
Quotient Clinical
ICON Development Solutions
Cetero Research, San Antonio
National Institute of Allergy and Infectious Diseases (NIAID)
Related Conditions
- Ebola Vaccine1
- Filovirus Infections1